<DOC>
	<DOC>NCT00424411</DOC>
	<brief_summary>To determine, in subjects with Type 2 Diabetes Mellitus: 1. Whether glycemic control can be achieved at least as effectively with an insulin regimen involving pre-meal EXUBERA™ (inhaled insulin) plus a single bedtime Ultralente injection as with a conventional subcutaneous insulin regimen involving 2 mixed Regular/NPH insulin injections per day. 2. The toleration and safety of EXUBERA™ (inhaled insulin) therapy and its effects after 6 months, if any, on measures of pulmonary function.</brief_summary>
	<brief_title>Six Month Clinical Trial Assessing Efficacy And Safety Of Inhaled Insulin In Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Type 2 Diabetes Stable insulin regimen of at least 2 injections per day Any smoking within the last 6 months. Smoking is not permitted at any time during this study. Subjects on insulin pump during 2 months prior to screening. Subjects with poorlycontrolled asthma, clinically significant chronic obstructive pulmonary disease, or other significant respiratory disease.</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2007</verification_date>
</DOC>